Evaluation of [99mTc/EDDA/HYNIC0]octreotide derivatives compared with [111In-DOTA0,Tyr3, Thr8]octreotide and [111In-DTPA0]octreotide: does tumor or pancreas uptake correlate with the rate of internalization?
about
Clinical applications of Gallium-68Synthesis and characterization of an (111)In-labeled peptide for the in vivo localization of human cancers expressing the urokinase-type plasminogen activator receptor (uPAR)Radiolabelled GLP-1 analogues for in vivo targeting of insulinomas.Applications of molecular imaging.Radiolabeled somatostatin receptor antagonists are preferable to agonists for in vivo peptide receptor targeting of tumors.Clinical results of radionuclide therapy of neuroendocrine tumours with 90Y-DOTATATE and tandem 90Y/177Lu-DOTATATE: which is a better therapy option?Twins in spirit - episode I: comparative preclinical evaluation of [(68)Ga]DOTATATE and [(68)Ga]HA-DOTATATEPET and SPECT Imaging of Tumor Biology: New Approaches towards Oncology Drug Discovery and Development.Gallium-68 DOTATOC PET/CT in vivo characterization of somatostatin receptor expression in the prostate[Lu]-DOTA-Tyr-octreotate: A Potential Targeted Radiotherapeutic for the Treatment of Medulloblastoma.Agonist-antagonist dilemma in molecular imaging: evaluation of a monomolecular multimodal imaging agent for the somatostatin receptor.The somatostatin receptor 2 antagonist 64Cu-NODAGA-JR11 outperforms 64Cu-DOTA-TATE in a mouse xenograft model.Design, Synthesis, In Vitro, and Initial In Vivo Evaluation of Heterobivalent Peptidic Ligands Targeting Both NPY(Y₁)- and GRP-Receptors-An Improvement for Breast Cancer Imaging?The tetraamine chelator outperforms HYNIC in a new technetium-99m-labelled somatostatin receptor 2 antagonist
P2860
Q26849276-A8C2C074-82E9-45F1-A89B-E432E0CD58F6Q33912826-ED9A5CBC-96A6-4874-AF13-1F8B616BA265Q34579936-3BD885DE-2BED-4300-A47F-EF3F7CE0B346Q35082412-D4C965FB-AB3F-4609-981F-35BD760F28A6Q35103872-0092AEF7-A562-4141-99E1-74BB68548935Q35201583-30C0526F-CFCE-4129-9041-C3D62CD9DC7FQ35478527-AC8363EB-0B01-4B4B-84DF-06D402CE9E9AQ37374442-8F4880FF-C7D7-4C60-A45D-F2E202145B9EQ38385895-5A568823-70DF-45AB-8C98-7F3852D5C324Q39606627-BA362E87-2D69-4304-8786-A7324888C21EQ40050040-15A74B40-595A-4F02-9BBE-7721606648C9Q52580539-2C984AB7-8306-4908-8A4A-A6B8E64FAA8AQ57757457-3F29A5E8-3BA6-4181-A674-1402723BCA2CQ58803952-B57E4CFC-A9B9-41B4-BEBB-CAD448DDC2DF
P2860
Evaluation of [99mTc/EDDA/HYNIC0]octreotide derivatives compared with [111In-DOTA0,Tyr3, Thr8]octreotide and [111In-DTPA0]octreotide: does tumor or pancreas uptake correlate with the rate of internalization?
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年学术文章
@wuu
2005年学术文章
@zh-cn
2005年学术文章
@zh-hans
2005年学术文章
@zh-my
2005年学术文章
@zh-sg
2005年學術文章
@yue
2005年學術文章
@zh
2005年學術文章
@zh-hant
name
Evaluation of [99mTc/EDDA/HYNI ...... h the rate of internalization?
@en
Evaluation of [99mTc/EDDA/HYNI ...... h the rate of internalization?
@nl
type
label
Evaluation of [99mTc/EDDA/HYNI ...... h the rate of internalization?
@en
Evaluation of [99mTc/EDDA/HYNI ...... h the rate of internalization?
@nl
prefLabel
Evaluation of [99mTc/EDDA/HYNI ...... h the rate of internalization?
@en
Evaluation of [99mTc/EDDA/HYNI ...... h the rate of internalization?
@nl
P2093
P1476
Evaluation of [99mTc/EDDA/HYNI ...... h the rate of internalization?
@en
P2093
Daniel Storch
Helmut R Mäcke
Jianhua Chen
Martin Béhé
Pia Powell
Renata Mikolajczak
P304
P407
P577
2005-09-01T00:00:00Z